Page 177 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Rituximab intensification during R-CHOP in DLBCL
Fig A2. Progression-free survival (PFS) by treatment arm for diffuse large B-cell lymphoma phenotype.
(A) non–germinal center B cell (GCB), (B) GCB, and (C) GCB unknown. P, progression, relapse, or death; R-CHOP, rituximab on day 1 of each cycle plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm A); RR-CHOP, rituximab on days 1 and 8 of first 4 cycles and day 1 of remaining cycles plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm B).
175
6b